Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alexander J. Beagle is active.

Publication


Featured researches published by Alexander J. Beagle.


JAMA Neurology | 2013

Seizures and epileptiform activity in the early stages of Alzheimer disease.

Keith A. Vossel; Alexander J. Beagle; Gil D. Rabinovici; Huidy Shu; Suzee E. Lee; Georges Naasan; Manu Hegde; Susannah Cornes; Maya L. Henry; Alexandra B. Nelson; William W. Seeley; Michael D. Geschwind; Maria Luisa Gorno-Tempini; Tina Shih; Heidi E. Kirsch; Paul A. Garcia; Bruce L. Miller; Lennart Mucke

IMPORTANCE Epileptic activity associated with Alzheimer disease (AD) deserves increased attention because it has a harmful impact on these patients, can easily go unrecognized and untreated, and may reflect pathogenic processes that also contribute to other aspects of the illness. We report key features of AD-related seizures and epileptiform activity that are instructive for clinical practice and highlight similarities between AD and transgenic animal models of the disease. OBJECTIVE To describe common clinical characteristics and treatment outcomes of patients with amnestic mild cognitive impairment (aMCI) or early AD who also have epilepsy or subclinical epileptiform activity. DESIGN Retrospective observational study from 2007 to 2012. SETTING Memory and Aging Center, University of California, San Francisco. PATIENTS We studied 54 patients with a diagnosis of aMCI plus epilepsy (n = 12), AD plus epilepsy (n = 35), and AD plus subclinical epileptiform activity (n = 7). MAIN OUTCOMES AND MEASURES Clinical and demographic data, electroencephalogram (EEG) readings, and treatment responses to antiepileptic medications. RESULTS Patients with aMCI who had epilepsy presented with symptoms of cognitive decline 6.8 years earlier than patients with aMCI who did not have epilepsy (64.3 vs 71.1 years; P = .02). Patients with AD who had epilepsy presented with cognitive decline 5.5 years earlier than patients with AD who did not have epilepsy (64.8 vs 70.3 years; P = .001). Patients with AD who had subclinical epileptiform activity also had an early onset of cognitive decline (58.9 years). The timing of seizure onset in patients with aMCI and AD was nonuniform (P < .001), clustering near the onset of cognitive decline. Epilepsies were most often complex partial seizures (47%) and more than half were nonconvulsive (55%). Serial or extended EEG monitoring appeared to be more effective than routine EEG at detecting interictal and subclinical epileptiform activity. Epileptic foci were predominantly unilateral and temporal. Of the most commonly prescribed antiepileptics, treatment outcomes appeared to be better for lamotrigine and levetiracetam than for phenytoin. CONCLUSIONS AND RELEVANCE Common clinical features of patients with aMCI- or AD-associated epilepsy at our center included early age at onset of cognitive decline, early incidence of seizures in the disease course, unilateral temporal epileptic foci detected by serial/extended EEG, transient cognitive dysfunction, and good seizure control and tolerability with lamotrigine and levetiracetam. Careful identification and treatment of epilepsy in such patients may improve their clinical course.


Annals of Neurology | 2016

Incidence and impact of subclinical epileptiform activity in Alzheimer's disease

Keith A. Vossel; Kamalini G. Ranasinghe; Alexander J. Beagle; Danielle Mizuiri; Susanne Honma; Anne F. Dowling; Sonja M. Darwish; Victoria Van Berlo; Deborah E. Barnes; Mary Mantle; Anna Karydas; Giovanni Coppola; Erik D. Roberson; Bruce L. Miller; Paul A. Garcia; Heidi E. Kirsch; Lennart Mucke; Srikantan S. Nagarajan

Seizures are more frequent in patients with Alzheimers disease (AD) and can hasten cognitive decline. However, the incidence of subclinical epileptiform activity in AD and its consequences are unknown. Motivated by results from animal studies, we hypothesized higher than expected rates of subclinical epileptiform activity in AD with deleterious effects on cognition.


NeuroImage: Clinical | 2014

Regional functional connectivity predicts distinct cognitive impairments in Alzheimer’s disease spectrum

Kamalini G. Ranasinghe; Leighton B. Hinkley; Alexander J. Beagle; Danielle Mizuiri; Anne F. Dowling; Susanne Honma; Mariel M. Finucane; Carole Scherling; Bruce L. Miller; Srikantan S. Nagarajan; Keith A. Vossel

Understanding neural network dysfunction in neurodegenerative disease is imperative to effectively develop network-modulating therapies. In Alzheimer’s disease (AD), cognitive decline associates with deficits in resting-state functional connectivity of diffuse brain networks. The goal of the current study was to test whether specific cognitive impairments in AD spectrum correlate with reduced functional connectivity of distinct brain regions. We recorded resting-state functional connectivity of alpha-band activity in 27 patients with AD spectrum − 22 patients with probable AD (5 logopenic variant primary progressive aphasia, 7 posterior cortical atrophy, and 10 early-onset amnestic/dysexecutive AD) and 5 patients with mild cognitive impairment due to AD. We used magnetoencephalographic imaging (MEGI) to perform an unbiased search for regions where patterns of functional connectivity correlated with disease severity and cognitive performance. Functional connectivity measured the strength of coherence between a given region and the rest of the brain. Decreased neural connectivity of multiple brain regions including the right posterior perisylvian region and left middle frontal cortex correlated with a higher degree of disease severity. Deficits in executive control and episodic memory correlated with reduced functional connectivity of the left frontal cortex, whereas visuospatial impairments correlated with reduced functional connectivity of the left inferior parietal cortex. Our findings indicate that reductions in region-specific alpha-band resting-state functional connectivity are strongly correlated with, and might contribute to, specific cognitive deficits in AD spectrum. In the future, MEGI functional connectivity could be an important biomarker to map and follow defective networks in the early stages of AD.


Annals of clinical and translational neurology | 2015

Network dysfunction in α-synuclein transgenic mice and human Lewy body dementia.

Meaghan Morris; Pascal E. Sanchez; Laure Verret; Alexander J. Beagle; Weikun Guo; Dena B. Dubal; Kamalini G. Ranasinghe; Akihiko Koyama; Kaitlyn Ho; Gui-Qiu Yu; Keith A. Vossel; Lennart Mucke

Dementia with Lewy bodies (DLB) is associated with the accumulation of wild‐type human α‐synuclein (SYN) in neurons and with prominent slowing of brain oscillations on electroencephalography (EEG). However, it remains uncertain whether the EEG abnormalities are actually caused by SYN.


Journal of Alzheimer's Disease | 2017

Relative Incidence of Seizures and Myoclonus in Alzheimer’s Disease, Dementia with Lewy Bodies, and Frontotemporal Dementia

Alexander J. Beagle; Sonja M. Darwish; Kamalini G. Ranasinghe; Alice L. La; Elissaios Karageorgiou; Keith A. Vossel

BACKGROUND Patients with Alzheimers disease (AD) are more prone to seizures and myoclonus, but relative risk of these symptoms among other dementia types is unknown. OBJECTIVE To determine incidence of seizures and myoclonus in the three most common neurodegenerative dementias: AD, dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). METHODS Our institutions medical records were reviewed for new-onset unprovoked seizures and myoclonus in patients meeting criteria for AD (n = 1,320), DLB (n = 178), and FTD (n = 348). Cumulative probabilities of developing seizures and myoclonus were compared between diagnostic groups, whereas age-stratified incidence rates were determined relative to control populations. RESULTS The cumulative probability of developing seizures after disease onset was 11.5% overall, highest in AD (13.4%) and DLB (14.7%) and lowest in FTD (3.0%). The cumulative probability of developing myoclonus was 42.1% overall, highest in DLB (58.1%). The seizure incidence rates, relative to control populations, were nearly 10-fold in AD and DLB, and 6-fold in FTD. Relative seizure rates increased with earlier age-at-onset in AD (age <50, 127-fold; 50-69, 21-fold; 70+, 2-fold) and FTD (age <50, 53-fold; 50-69, 9-fold), and relative myoclonus rates increased with earlier age-at-onset in all groups. Seizures began an average of 3.9 years after the onset of cognitive or motor decline, and myoclonus began 5.4 years after onset. CONCLUSIONS Seizures and myoclonus occur with greater incidence in patients with AD, DLB, and FTD than in the general population, but rates vary with diagnosis, suggesting varied pathomechanisms of network hyperexcitability. Patients often experience these symptoms early in disease, suggesting hyperexcitability could be an important target for interventions.


Brain | 2017

Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants

Kamalini G. Ranasinghe; Leighton B. Hinkley; Alexander J. Beagle; Danielle Mizuiri; Susanne Honma; Ariane E. Welch; Isabel Hubbard; Maria Luisa Mandelli; Zachary A. Miller; Coleman Garrett; Alice La; Adam L. Boxer; John F. Houde; Bruce L. Miller; Keith A. Vossel; Maria Luisa Gorno-Tempini; Srikantan S. Nagarajan

Primary progressive aphasia is a syndrome characterized by progressive loss of language abilities with three main phenotypic clinical presentations, including logopenic, non-fluent/agrammatic, and semantic variants. Previous imaging studies have shown unique anatomic impacts within language networks in each variant. However, direct measures of spontaneous neuronal activity and functional integrity of these impacted neural networks in primary progressive aphasia are lacking. The aim of this study was to characterize the spatial and temporal patterns of resting state neuronal synchronizations in primary progressive aphasia syndromes. We hypothesized that resting state brain oscillations will show unique deficits within language network in each variant of primary progressive aphasia. We examined 39 patients with primary progressive aphasia including logopenic variant (n = 14, age = 61 ± 9 years), non-fluent/agrammatic variant (n = 12, age = 71 ± 8 years) and semantic variant (n = 13, age = 65 ± 7 years) using magnetoencephalographic imaging, compared to a control group that was matched in age and gender to each primary progressive aphasia subgroup (n = 20, age = 65 ± 5 years). Each patient underwent a complete clinical evaluation including a comprehensive battery of language tests. We examined the whole-brain resting state functional connectivity as measured by imaginary coherence in each patient group compared to the control cohort, in three frequency oscillation bands-delta-theta (2-8 Hz); alpha (8-12 Hz); beta (12-30 Hz). Each variant showed a distinct spatiotemporal pattern of altered functional connectivity compared to age-matched controls. Specifically, we found significant hyposynchrony of alpha and beta frequency within the left posterior temporal and occipital cortices in patients with the logopenic variant, within the left inferior frontal cortex in patients with the non-fluent/agrammatic variant, and within the left temporo-parietal junction in patients with the semantic variant. Patients with logopenic variant primary progressive aphasia also showed significant hypersynchrony of delta-theta frequency within bilateral medial frontal and posterior parietal cortices. Furthermore, region of interest-based analyses comparing the spatiotemporal patterns of variant-specific regions of interest identified in comparison to age-matched controls showed significant differences between primary progressive aphasia variants themselves. We also found distinct patterns of regional spectral power changes in each primary progressive aphasia variant, compared to age-matched controls. Our results demonstrate neurophysiological signatures of network-specific neuronal dysfunction in primary progressive aphasia variants. The unique spatiotemporal patterns of neuronal synchrony signify diverse neurophysiological disruptions and pathological underpinnings of the language network in each variant.


Alzheimers & Dementia | 2012

Subclinical epileptiform activity in Alzheimer's disease

Keith A. Vossel; Alexander J. Beagle; Manu Hegde; Mary Mantle; Heidi E. Kirsch; Paul A. Garcia; Susanne Honma; Anne M. Findlay; Gil D. Rabinovici; William J. Jagust; Srikantan S. Nagarajan; Bruce L. Miller; Erik D. Roberson; Lennart Mucke

Background: Pro-inflammatory cytokines have been detected in brains of individuals with Alzheimer’s disease (AD) andmay play a significant role in the pathogenesis of AD. Our earlier reports investigated glial cell responses to LPS and A b, by upregulating the expression of cytokines TNFa, IL-1 b, and IL-6, as well as iNOS and COX-2. The present study was undertaken to investigate the therapeutic benefits of AICAR (a potent activator of AMP-activated protein kinase) in blocking the pro-oxidant/proinflammatory responses inmicroglia. Objectives: Ourmain objectives were a) to understand the activation aswell release of cytokines from activatedmicroglia in response to accumulated A b, and possible therapeutic benefits of AICAR. Methods: BV-2 microglia were used in these studies to understand LPS/ SMase/A b stimulated signaling mechanisms of NF k B pathway leading to the release of NO, ROS generation , release of inflammatory cytokine (TNFa, IL-1 b, IL-6) as well the scavenging macrophage like phagocytic functions of microglia.Results:AICAR inhibits LPS, and Smase activated cytokine release and NO production. AICAR also does promote A b phagocytosis. Further we observed a reduction in the stress signalingwith a significant lowering in p-ERK, p-p38, p-Akt (ser 473) as well as significant reduction of proteins such as p-NIK, p-IKK a/b and in p-p65 translocation. Conclusions: Microglia play an active role in triggering the immune cytokine responses in the neuro-inflammatory process ofAD. AICAR treatment effectively blocked cytokine release, A b phagocytosis by regulating NF k B pathways and perhaps is effective for therapeutics of AD.


Neurobiology of Aging | 2017

Abnormal vocal behavior predicts executive and memory deficits in Alzheimer's disease

Kamalini G. Ranasinghe; Jeevit Gill; Hardik Kothare; Alexander J. Beagle; Danielle Mizuiri; Susanne Honma; Maria Luisa Gorno-Tempini; Bruce L. Miller; Keith A. Vossel; Srikantan S. Nagarajan; John F. Houde


Brain | 2016

Neuroeconomic dissociation of semantic dementia and behavioural variant frontotemporal dementia

Winston Chiong; Kristie Wood; Alexander J. Beagle; Ming Hsu; Andrew S. Kayser; Bruce L. Miller; Joel H. Kramer


Alzheimers & Dementia | 2018

DISTINCT NEURAL OSCILLATION ABNORMALITIES ASSOCIATED WITH AMYLOID-BETA AND TAU IN ALZHEIMER’S DISEASE

Kamalini G. Ranasinghe; Jungho Cha; Leighton B. Hinkley; Alexander J. Beagle; Danielle Mizuiri; Susanne Honma; Viktoriya Bourakova; William J. Jagust; Bruce L. Miller; Gil D. Rabinovici; Srikantan S. Nagarajan; Keith A. Vossel

Collaboration


Dive into the Alexander J. Beagle's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Susanne Honma

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lennart Mucke

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge